ACET - Aceto Corporation

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
0.1345
0.0000 (0.00%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close0.1345
Open0.1590
Bid0.0000 x 4000
Ask0.0000 x 800
Day's Range0.1330 - 0.1650
52 Week Range0.1330 - 0.1650
Volume6,744,238
Avg. VolumeN/A
Market CapN/A
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateNov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire

    ACETO Completes the Sale of Its Chemicals Business Assets

    ACETO Corporation (ACETQ) announced today that it has completed the previously disclosed sale of its chemicals business assets to an affiliate of New Mountain Capital, a leading growth-oriented investment firm with over $20 billion in assets under management.

  • GlobeNewswire

    ACETO Completes the Sale of Rising Pharmaceuticals

    PORT WASHINGTON, N.Y., April 22, 2019 -- ACETO Corporation (Nasdaq: ACETQ), an international company engaged in the development, marketing, sale and distribution of Human.

  • GlobeNewswire

    ACETO to Sell its Chemicals Business Assets to New Mountain Capital

    ACETO Corporation (ACETQ), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today that it has agreed to sell its chemicals business assets to an affiliate of New Mountain Capital (“NMC”), a leading growth-oriented investment firm with over $20 billion in assets under management. The asset purchase agreement was entered into following the conclusion of a court-supervised sale process conducted under Section 363 of the U.S. Bankruptcy Code. Under that process, an asset purchase agreement between Aceto and NMC was executed, dated February 18, 2019, to sell the chemical business assets as the “stalking horse agreement”.

  • GlobeNewswire

    ACETO Receives Court Approval of “Stalking Horse” Agreement to Sell Rising Pharmaceuticals to Shore Suven Pharma, Inc.

    ACETO Corporation (ACETQ), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today that it has received approval from the U.S. Bankruptcy Court  to sell the assets of Rising Pharmaceuticals and Rising’s subsidiaries to Shore Suven Pharma, Inc. for gross cash proceeds of $15 million, plus the assumption of operating liabilities and customer obligations related to the acquired business, on a cash-free and debt-free basis. The sale was conducted through a Court-supervised process under Section 363 of the Bankruptcy Code.  Under that process, Shore Suven Pharma’s purchase agreement served as the “stalking horse agreement” and an auction would have been conducted had the Company received qualified offers from other bidders reflecting potentially higher and/or otherwise better terms.

  • 6 Poorly Performing Stocks
    GuruFocus.com

    6 Poorly Performing Stocks

    The return on equity of -211.13% and return on assets of -41.80% are underperforming 84% of companies in the Global Drug Manufacturers - Specialty and Generic industry. The company's largest guru shareholder is Jim Simons (Trades, Portfolio)' Renaissance Technologies with 4.75% of outstanding shares, followed by Chuck Royce (Trades, Portfolio) with 1.53%. The return on equity of -0.71% and return on assets of -0.42% are underperforming 72% of companies in the Global Coal industry.

  • GlobeNewswire

    ACETO Enters into “Stalking Horse” Agreement to Sell Rising Pharmaceuticals

    ACETO Corporation (ACET), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, announced today that it has entered into a “stalking-horse” asset purchase agreement with Shore Suven Pharma, Inc. to sell the assets of Rising Pharmaceuticals and Rising’s subsidiaries for gross cash proceeds of $15 million, plus the assumption of operating liabilities and customer obligations related to the acquired business on a cash-free and debt-free basis. Shore Suven Pharma, Inc. is a joint venture between Suven Life Sciences Limited, an India-based provider of contract research and manufacturing services for the global life sciences industry, and Shore Pharma Investments, LLC, a company founded by Vimal Kavuru to acquire generic drug assets.

  • ACCESSWIRE

    Watch These Four Healthcare Stocks Set The Pace on Thursday

    Premier Health Group (OTC:PHGRF) (CSE:PHGI), Aceto Corporation (ACET), OPKO Health Inc (OPK), and Midatech Pharma plc (NASDAQ:MTP) represent 4 healthcare stocks to pay attention to on Thursday. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company which is laser-focused on developing innovative approaches that combine human skill-based expertise with state-of-the-art technologies to champion products and services meant to improve the quality of life for consumers. Premier Health Group (OTC:PHGRF) (CSE:PHGI) today announced the launch of at technology-enabled mental health counseling service for patients in urban centers and remote and underserved populations.

  • GlobeNewswire

    ACETO Announces Receipt of Nasdaq Notice Due to Delay in Filing Form 10-Q for the Fiscal Quarter Ended December 31, 2018

    PORT WASHINGTON, N.Y., Feb. 20, 2019 -- ACETO Corporation (Nasdaq: ACET), an international company engaged in the development, marketing, sale and distribution of Human Health.

  • GlobeNewswire

    ACETO Announces Proposed Sale of its Chemicals Business Assets to New Mountain Capital for $338 million

    ACETO and its U.S. Subsidiaries File Voluntary Chapter 11 Petitions to Facilitate SaleSecures Commitment for Debtor-in-Possession Financing to Support Normal Course.

  • GlobeNewswire

    New Research Coverage Highlights NiSource, Callaway Golf, TEGNA, The Manitowoc, CTS, and Aceto — Consolidated Revenues, Company Growth, and Expectations for 2019

    NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Thomson Reuters StreetEvents

    Edited Transcript of ACET earnings conference call or presentation 9-Nov-18 2:00pm GMT

    Q1 2019 Aceto Corp Earnings Call

  • Business Wire

    Robbins Arroyo LLP: Lawsuit Says Aceto Corporation (ACET) Misled Shareholders

    Shareholder rights law firm Robbins Arroyo LLP reminds shareholders that purchasers of Aceto Corporation (ACET) have sued the company's officers and directors for breaches of their fiduciary duties between August 25, 2017 and April 18, 2018. Aceto develops, markets, sells, and distributes finished dosage form generic pharmaceuticals and nutraceutical products, among other products. According to the complaint, Aceto assured investors that the company's internal controls over financial reporting were effective.

  • Simply Wall St.

    Could The Aceto Corporation (NASDAQ:ACET) Ownership Structure Tell Us Something Useful?

    If you want to know who really controls Aceto Corporation (NASDAQ:ACET), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as shareholders, Read More...

  • Associated Press

    Aceto: Fiscal 1Q Earnings Snapshot

    The Port Washington, New York-based company said it had a loss of 59 cents per share. The chemical company posted revenue of $164.4 million in the period. The company's shares closed at $2.03. A year ago, ...

  • GlobeNewswire

    ACETO Reports Fiscal 2019 First Quarter Results

    PORT WASHINGTON, N.Y., Nov. 08, 2018 -- ACETO Corporation (NASDAQ:ACET), an international company engaged in the development, marketing, sale and distribution of Human Health.

  • GlobeNewswire

    ACETO Corporation Adopts Rights Plan Designed to Preserve Valuable Net Operating Loss Carryforwards and Other Tax Benefits

    ACETO Corporation (ACET) today announced that its Board of Directors has adopted a tax asset protection rights plan (the “Rights Plan”).  The Rights Plan is designed to preserve ACETO’s net operating loss carryforwards (NOLs) and other significant tax benefits which may be available to reduce potential future tax liabilities. ACETO’s Board determined that the Rights Plan was warranted and in the best interests of all stockholders due to the substantial dollar amount of the NOLs and other tax assets and the importance of these potential benefits for future cash flows.  The Rights Plan is similar to the tax asset protection rights agreements adopted by numerous other public companies seeking to protect their NOLs and other tax benefits.  The Rights Plan and the rights issued under the Rights Plan will expire on November 5, 2021, or on an earlier date if certain events occur, as described more fully in the Rights Plan.

  • ACCESSWIRE

    Update: Lawsuit for Investors in Aceto Corporation (NASDAQ: ACET) Shares Announced by Shareholders Foundation

    SAN DIEGO, CA / ACCESSWIRE / October 22, 2018 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares Aceto Corporation (NASDAQ: ACET). The plaintiff seeks ...